Last reviewed · How we verify
Aldadiene (CANRENONE)
At a glance
| Generic name | CANRENONE |
|---|---|
| Drug class | canrenone |
| Target | Mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19 (PHASE2)
- Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study (PHASE3)
- MRA and ARB Treatment in Screening of Primary Aldosteronism
- Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation. (PHASE4)
- Canrenone Effects on Cardiovascular Mortality in Patients With Congestive Heart Failure (the Coffee-it Study)
- Canrenone as Add-on in Patients With Essential Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aldadiene CI brief — competitive landscape report
- Aldadiene updates RSS · CI watch RSS